International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update

Amelia Evoli, Pushpa Narayanaswami, Donald B. Sanders, Gil Wolfe, Michael Benatar, Gabriel Cea, Nils Erik Gilhus, Isabel Illa, Nancy L. Kuntz, Janice Massey, Arthur Melms, Hiroyuki Murai, Michael Nicolle, Jacqueline Palace, David Richman, Jan Verschuuren

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

OBJECTIVE: To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. METHODS: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting "yes") was used to approve minor changes in grammar and syntax to improve clarity. RESULTS: The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment. CONCLUSION: This updated formal consensus guidance of international MG experts, based on new evidence, provides recommendations to clinicians caring for patients with MG worldwide.
Lingua originaleEnglish
pagine (da-a)114-122
Numero di pagine9
RivistaNeurology
Volume96
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Antibodies, Monoclonal, Humanized
  • Consensus
  • Disease Management
  • Humans
  • Thymectomy
  • Immunosuppressive Agents
  • Methotrexate
  • Myasthenia Gravis
  • Rituximab
  • Immune Checkpoint Inhibitors

Fingerprint Entra nei temi di ricerca di 'International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update'. Insieme formano una fingerprint unica.

Cita questo